Adding serplulimab to chemotherapy prolonged overall survival in patients with previously untreated, extensive-stage small cell lung cancer.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Pembrolizumab is a potential new treatment option for stage IB-IIIA non-small cell lung cancer after complete resection, according to researchers.
Many patients with advanced non-small cell lung cancer do not survive long enough to receive second-line therapy, a real-world study suggests.
Adjuvant osimertinib continues to demonstrate a disease-free survival benefit vs placebo in resected, stage IB-IIIA, EGFR-mutated non-small cell lung cancer.
The prevalence of metastatic cancers in the US has risen in recent years and will increase further by 2025, according to researchers.
A CT-based follow-up approach improved early detection of lung cancer recurrence and second primary lung cancers but did not improve survival.
Survivors of Hodgkin lymphoma may have a higher risk of developing lung cancer than former smokers, a study suggests.
Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.
Detection of ctDNA and early changes in ctDNA levels may predict treatment outcomes in patients with advanced solid tumors.
Disparities in cancer diagnoses among pediatric patients are partly a result of disparities in health insurance coverage, a study suggests.